BRPI1014247A2 - reversão da discinesia induzida pela l-dopa por ligantes de receptores nocotínicos neuronais. - Google Patents

reversão da discinesia induzida pela l-dopa por ligantes de receptores nocotínicos neuronais.

Info

Publication number
BRPI1014247A2
BRPI1014247A2 BRPI1014247A BRPI1014247A BRPI1014247A2 BR PI1014247 A2 BRPI1014247 A2 BR PI1014247A2 BR PI1014247 A BRPI1014247 A BR PI1014247A BR PI1014247 A BRPI1014247 A BR PI1014247A BR PI1014247 A2 BRPI1014247 A2 BR PI1014247A2
Authority
BR
Brazil
Prior art keywords
nocotinic
dopa
neuronal
reversal
receptor ligands
Prior art date
Application number
BRPI1014247A
Other languages
English (en)
Inventor
Kristen Jordan
Merouane Bencherif
Sharon Rae Letchworth
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of BRPI1014247A2 publication Critical patent/BRPI1014247A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1014247A 2009-06-17 2010-06-15 reversão da discinesia induzida pela l-dopa por ligantes de receptores nocotínicos neuronais. BRPI1014247A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18789609P 2009-06-17 2009-06-17
PCT/US2010/038605 WO2010147938A2 (en) 2009-06-17 2010-06-15 Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands

Publications (1)

Publication Number Publication Date
BRPI1014247A2 true BRPI1014247A2 (pt) 2016-04-12

Family

ID=43357005

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014247A BRPI1014247A2 (pt) 2009-06-17 2010-06-15 reversão da discinesia induzida pela l-dopa por ligantes de receptores nocotínicos neuronais.

Country Status (14)

Country Link
US (1) US20120157477A1 (pt)
EP (1) EP2442810A4 (pt)
JP (1) JP2012530707A (pt)
KR (1) KR20120061047A (pt)
CN (1) CN102802630A (pt)
AU (1) AU2010260265A1 (pt)
BR (1) BRPI1014247A2 (pt)
CA (1) CA2763551A1 (pt)
IL (1) IL216458A0 (pt)
MX (1) MX2011013860A (pt)
NZ (1) NZ596734A (pt)
RU (1) RU2012101424A (pt)
WO (1) WO2010147938A2 (pt)
ZA (1) ZA201108706B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
RS59687B1 (sr) * 2013-01-22 2020-01-31 Vistagen Therapeutics Inc Oblici doziranja i terapeutske primene l-4-hlorkinurenina
CN114533737B (zh) * 2016-04-07 2024-05-31 奥伊斯特普安生物制药公司 治疗眼部病状的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Also Published As

Publication number Publication date
KR20120061047A (ko) 2012-06-12
IL216458A0 (en) 2012-01-31
ZA201108706B (en) 2012-07-25
EP2442810A4 (en) 2012-11-28
WO2010147938A2 (en) 2010-12-23
CN102802630A (zh) 2012-11-28
US20120157477A1 (en) 2012-06-21
MX2011013860A (es) 2012-01-30
WO2010147938A3 (en) 2011-05-19
AU2010260265A1 (en) 2011-12-22
CA2763551A1 (en) 2010-12-23
EP2442810A2 (en) 2012-04-25
JP2012530707A (ja) 2012-12-06
NZ596734A (en) 2014-02-28
RU2012101424A (ru) 2013-07-27

Similar Documents

Publication Publication Date Title
BR112013030885A2 (pt) composição de stevia.
BR112012015778A2 (pt) dispositivo de sinalização.
BR112013033191A2 (pt) sinalização de imagem de referência
BRPI1007047A2 (pt) Biorrefino irganosolv de cana-de-açúcar inteira.
IT1398793B1 (it) Motociclo.
BRPI1008949A2 (pt) Cetoenóis haloalquilmetilenóxi-fenil-substituídos.
EP2396630A4 (en) FLOW
BRPI1014802A2 (pt) pró-fármacos de triptolida.
BRPI1014090A2 (pt) produto de bebida instantânea
BRPI1014388A2 (pt) preparação de sólido.
IT1397667B1 (it) Rotismo.
BRPI1016192A2 (pt) derivados de soxazol.
DK2442870T3 (da) Pyrazinooxazepin-derivater.
EP2509287A4 (en) SLIDING AND TILTING MECHANISM
BRPI1009641A2 (pt) Composição de complexo protrombótico
BR112012002307A2 (pt) mecanismo de came.
PT2523567T (pt) Recuperacão de água
BRPI1014412A2 (pt) nanocapsula de poliarginina
BRPI1014247A2 (pt) reversão da discinesia induzida pela l-dopa por ligantes de receptores nocotínicos neuronais.
IT1397303B1 (it) Poligalattomannano cationico purificato esente da gliossale.
EP2453746A4 (en) TAZAROTENDERIVATE
BR112012002752A8 (pt) métodos de encher com cascalho poços de trechos extensos
IT1400895B1 (it) Motociclo.
BR112012001617A2 (pt) Preparação de 1,4-diaminobutano
ES2397885B1 (es) Derivados de colismicina.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2372 DE 21-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.